| Literature DB >> 30364783 |
David Friedel1, Stavros Nicholas Stavropoulos2.
Abstract
Endoscopic submucosal dissection (ESD) is well established in Asia as a modality for selected advanced lesions of both the upper and lower gastrointestinal tract, but ESD has not attained the same niche in the West due to a variety of reasons. These include competition from traditional surgery, minimally invasive surgery and endoscopic mucosal resection. Other obstacles to ESD introduction in the West include time commitment for learning and doing procedures, a steep learning curve, special equipment, lack of mentors, cost issues, interdisciplinary conflicts, concern regarding complications and lack of support from institutions and interfacing departments. There are intrinsic differences in pathology prevalence (e.g., early gastric cancer) between the two regions that are less conducive for ESD implementation in the West. We will elaborate on these issues and suggest measures as well as a protocol to overcome these obstacles and hopefully allow introduction of ESD as a tenable option for appropriate patients.Entities:
Keywords: Barrett’s esophagus; Colon cancer; Endoscopic submucosal dissection; Endoscopy training; Gastric cancer; Rectal cancer
Year: 2018 PMID: 30364783 PMCID: PMC6198314 DOI: 10.4253/wjge.v10.i10.225
Source DB: PubMed Journal: World J Gastrointest Endosc
Endoscopic mucosal resection vs endoscopic submucosal dissection for early Barrett’s and esophagogastric junction neoplasia
| Recurrence rate | 6 | 1/333 (0.3) | 5 | 10/380 (2.6) | 8.55 (0.91, 80.0) | 0.06 |
| Perforation | 6 | 5/335 (1.5) | 9 | 8/686 (1.2) | 1.07 (0.20, 5.62) | 0.94 |
| Delayed bleeding | 6 | 7/335 (2.1) | 9 | 8/686 (1.2) | 0.46 (0.12, 1.75) | 0.26 |
| Stricture | 5 | 7/207 (3.4) | 7 | 3/456 (0.7) | 0.21 (0.03, 1.41) | 0.11 |
| Method | No. of studies | Pooled procedure time (95%CI) | ||||
| EMR | 2 | 36.7 (34.5, 38.9) | ||||
| ESD | 5 | 83.3 (57.4, 109.2) |
Modified from Komeda et al[7]. EMR: Endoscopic mucosal resection; ESD: Endoscopic submucosal dissection.
Endoscopic submucosal dissection for Barrett’s high-grade intraepithelial neoplasia and early adenocarcinoma
| Subjects | 75 | 19 | 22 | 17 |
| Study design | Retrospective | Retrospective | Retrospective | Prospective |
| Rates of resection | ||||
| 90% | 100% | 96% | 100% | |
| R0 resection rate | 64% | 85% | 82% | 59% |
| Curative rate | 64% | 65% | 77% | 93% |
| Adverse events | ||||
| Bleeding | 3% | 4% | 9% | 0% |
| Perforation | 4% | 0% | 5% | 12% |
| Stricture | 60% | 15% | 14% | 0% |
Modified from Terheggen et al[7].
Figure 1NYU Winthrop esophageal endoscopic submucosal dissection experience. A: ESD characteristics and histopathology; B: Histology of lesions; C: Learning effect on procedure time; D: Learning effect on R0 resection rate. AEs: Adverse events; ESD: Endoscopic submucosal dissection.
Endoscopic submucosal dissection for early gastric cancer in the West
| Cardoso et al[ | 15 | 1 | 0 | 80 | 74 | 8 | 8 |
| Catalano et al[ | 12 | 2.5 | 0 | 92 | 92 | 8 | 8 |
| Probst et al[ | 91 | 2.3 | 0 | 87 | 72 | 12 | 5.6 |
| Schumacher et al[ | 28 | 2 | 3.4 | 90 | 64 | 7 | 11 |
| Pimental-Nunes et al[ | 136 | 2.2 | 0 | 94 | 82 | 7 | 7 |
Modified from Oyama et al[2].
Endoscopic submucosal dissection for early gastric cancer
| Mucosal cancer | Submucosal cancer | |||||
| No ulceration | Ulcerated | SM1 | SM2 | |||
| ≤ 20 | > 20 | ≤ 30 | > 30 | ≤ 30 | Any size | |
| Intestinal | ||||||
| Diffuse | ||||||
Guideline criteria for ESD;
Consider surgery;
Expanded criteria for ESD;
Surgery (gastrectomy + lymph node dissection). ESD: Endoscopic submucosal dissection.
Major Western endoscopic submucosal dissection series for early gastric cancer n (%)
| 179 subjects | 53 subjects | 87 subjects | 30 subjects | |
| Post ESD endoscopic follow-up | 53/53 (100) | 84/87 (97) | 27/39 (69) | < 0.001 |
| Follow-up median (mo) | 51 | 56 | 36 | NS |
| Curative resection | 47/53 (89) | 65/87 (75) | 0 | 0.07 |
| Local recurrence | 0 | 4/84 (5) | 3/27 (11) | 0.06 |
| Post ESD surgery | 0 | 3/87 (3) | 12/39 (31) | < 0.001 |
| Metastases | 0 | 1/84 (1) | 3/27 (11) | 0.005 |
| Gastric cancer mortality | 0 | 0 | 3 (8) | 0.004 |
| All-cause mortality | 7 (13) | 16 (18) | 11 (28) | 0.19 |
One hundred and seventy-nine ESD procedures for EGC over 12 years-about 15/year (modest compared to Asian centers). This Western center’s learning curve: 1st block of ESD’s (1-96) compared to 2nd block (97-191). R0 resection increased from 60% (57/96) to 93% (88/95) (P < 0.001). Median procedure time decreased from 148 to 110 min (P < 0.001). Modified from Probst et al[25]. ESD: Endoscopic submucosal dissection; NS: Not significant; EGC: Early gastric cancer.
Figure 2Endoscopic submucosal dissection of early gastric cancer (NYU-Winthrop).
Cost analysis-endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal lesions
| ESD |
| Selective ESD prevented 19 additional surgeries per 1000 cases at slightly lower cost compared with WF-EMR |
| U-ESD could prevent an additional 13 surgeries per 1000 cases compared with S-ESD but at substantially increased cost of > 21000 dollars (Australian) per surgery avoided |
| Expanded ESD criteria (Japanese Gastrointestinal Endoscopy Society) adding mainly granular lesions > 4 cm added little additional benefit |
| Authors stated U-ESD is “unjustified” given WF-EMR effectiveness for benign lesions of LR-SMIC |
| Subgroup analysis of only rectal lesions concluded WF-EMR including trans-anal resection was as effective as S-ESD and still less costly |
| Because of the higher prevalence of SMIC in the rectum, the incremental cost per surgery avoided by U-ESD decreased to $87066 and dropped to $32132 among non-granular rectal lesions. U-ESD became the least costly and most effective strategy among higher risk non-granular Paris 0-is rectal lateral spreading lesions |
| Study design: Selective ESD strategy was employed for lesions suspicious for SMIC-all others had WF-EMR. Pathology after ESD revealing high - risk SMIC necessitated surgery. LR-SMIC on pathology at the ESD were considered cured |
After Behin. Gut 2017. U-ESD: Universal ESD; ESD: Endoscopic submucosal dissection; EMR: Endoscopic mucosal resection; LR-SMIC: Low prevalence of low risk submucosal invasive cancer; WF-EMR: Wide field endoscopic mucosal resection; S-ESD: Selective endoscopic submucosal dissection; SMIC:submucosal invasive cancer.
Caveats for the endoscopic submucosal dissection pioneer
| Start clinical ESD only after extensive pre-clinical training |
| Start with easier lesions |
| Avoid “unprincipled ESD” |
| Record and monitor closely outcomes and complications- consider registry and videos |
| Be familiar with techniques for endoscopic management of complications |
| The main complications (perforation and bleeding) can almost always be managed (or even prevented in the case of bleeding) by skillful application of clips and coagulation |
| Experience with endoscopic clip placement and coagulation grasper application is essential (experience with endoscopic suturing is highly desirable) |
| Avoid mistakes in selecting and scheduling cases-many referral reports lack detailed information on morphology, size, location, prior manipulation |
| Morphology ( |
| Index biopsies may be misleading (obtained from the periphery rather than depressed areas of 2c or 1s lesions missing a carcinoma) |
| Biopsies yielding only dysplasia may result in a publicly delayed resection of cancer |
| Concordance of biopsy results and ultimate post-resection pathology is fair at best |
| EDUCATE your referring physicians-AVOID inappropriate India ink tattooing and “partial snare resections”/hot forceps/jumbo forceps for “diagnosis or “attempted” hasty resections (tackling lesions where probability of complete EMR is low) |
| Lack of experience in delineating early GI cancer main lead to excessive sampling biopsies |
| DISCOURAGE APC to” vaporize “grossly” evident residual tumor or aggressive/many biopsies of delicate flat lesions (SSA’s) |
| ENCOURAGE: (1) detailed descriptions: size, morphology; (2) lots of pictures; (3) giving print out with color pictures to the patient and d) having referring physicians transit “money” shots of lesion to you |
| Put post - resection specimens on corkboard and educate pathologist about specifics of resection |
| Pathologists should properly orient specimens with ≤ 2 mm slices |
| Pathology report should comment on adequacy of resection including deep and lateral margins with measurement of submucosal invasion with micrometer measurements as well as the differentiation (G1-G3) |
| Optimally there should be desmin staining of the muscularis mucosa noting the pattern of SM invasion, |
| Comment should be made regarding lymphovascular invasion with elastin Van Gieson stain to delineate venules and the D2 – 40 immunostain for lymphatics (important) |
| Multidisciplinary input and communication including nursing, technicians, anesthesiologists, surgeons and oncologists |
| The patient should be evaluated as dictated by medical history by internists, cardiology and pulmonary medicine with particular attention to anticoagulants and antiplatelet drugs |
| Ergonomic considerations are given to both ESD operator and patient |
ESD: Endoscopic submucosal dissection; GI: Gastrointestinal.
Benefits of institution endoscopic submucosal dissection program
| Potential benefit in avoiding surgery/organ resection |
| “Downstream revenue “from increased services and subsequent referral to surgery/oncology of patients (possibly up to 20% of ESD’s performed) |
| Enhancement of overall institutional prestige |
| ESD is a necessity for any institution purporting to be a tertiary referral center for luminal GI tract |
| Enhanced recruitment of trainees and faculty after establishment of ESD program |
ESD: Endoscopic submucosal dissection; GI: Gastrointestinal.
Figure 3Gastric endoscopic submucosal dissection difficulty by location. ESD: Endoscopic submucosal dissection.
Figure 4Relative endoscopic submucosal dissection difficulty by location. ESD: Endoscopic submucosal dissection; EGJ: Esophagogastric junction.
Figure 5Chronology of endoscopic submucosal dissection development in a Western Center. ESD: Endoscopic submucosal dissection; STER: submucosal tunnel endoscopic resection; EFTR: endoscopic full-thickness resection.
Western Center initial endoscopic submucosal dissection series n (%)
| Total Lesions | 38 (43) | Total lesions | 51 (57) |
| Size, mean millimeters (range) | 26 (5-90) | Size, mean millimeters (range) | 18 (8-55) |
| Complete | 20 (53) | Complete | 38 (75) |
| Complete 2-piece resection | 5 (10) | ||
| incomplete resection | 8 (15) | ||
| Histologic diagnosis | Histologic diagnosis | ||
| T1 carcinomas/adenomas with HGD | 16 (42) | GIST | 12 (23) |
| Adenomas w/o HGD | 10 (26) | Pancreatic rests | 11 (21) |
| No residual adenoma granulation tissue | 11 (29) | Lipomas | 8 (16) |
| Unclassified | 1 (3) | Carcinoids | 6 (12) |
| Granular cell tumors | 3 (6) | ||
| Leiomyomas | 8 (16) | ||
| Other | 3 (6) | ||
SETs: Subepithelial tumors; EMNS: Early mucosal neoplasm; GIST: Gastrointestinal stromal tumors; HGD: High grade dysplasia.
Figure 6NYU-Winthrop endoscopic submucosal dissection experiences. A: ESD pathology; B: ESD R0 rates; C: UGI ESD dissection speed. ESD: Endoscopic submucosal dissection.
Figure 7Traction in endoscopic submucosal dissection. A: Traction via clip on string; B: Traction via pulley effect with two clips.